Medpage Today on MSN12h
Alzheimer's Lecanemab Treatment Up to 36 Months Supported by Extension StudySAN DIEGO -- Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 ...
Drew Struzan, best known for his iconic work on movie posters for some of the biggest Hollywood blockbusters, is battling Alzheimer’s and “fighting for his life.” His wife Dylan shared the news on ...
STOCKHOLM, SE / ACCESS Newswire / April 7, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing ...
We’re sorry to report that legendary poster artist Drew Struzan, now 78, can no longer paint or even sign his art and is, in ...
Validation data presented at the 2025 Alzheimer's & Parkinson's Diseases (AD/PD) Conference confirms two novel NeuLogiq® Platform endpoints show greater separation with Alzheimer's pTau217 pathology ...
At this week’s International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, researchers from Suntec Medical Inc. and collaborators presented a poster ...
News-Medical.Net on MSN3d
NUZ-001 shows positive results in human 3D brain modelNeurizon Therapeutics Limited (“Neurizon”), a clinical-stage biotech company dedicated to advancing treatments for ...
Cognito Therapeutics to Present New Data on Spectris’™ Impact on Brain Structure in Alzheimer’s Disease at AD/PD 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback